Post hoc Analysis of Clinical Outcomes in Placebo-and Pirfenidone-treated Patients with IPF Stratified by BMI and Weight Loss - Laboratoire Traitement du Signal et de l'Image Accéder directement au contenu
Article Dans Une Revue Respiration Année : 2022

Post hoc Analysis of Clinical Outcomes in Placebo-and Pirfenidone-treated Patients with IPF Stratified by BMI and Weight Loss

Résumé

Background - Weight loss is frequently reported in patients with idiopathic pulmonary fibrosis (IPF) and may be associated with worse outcomes in these patients. Objective - The aim of this study was to investigate the relationships between body mass index (BMI) and weight loss, and outcomes over 1 year in patients with IPF. Methods - Data were included from placebo patients enrolled in ASCEND (NCT01366209) and CAPACITY (NCT00287716 and NCT00287729), and all patients in INSPIRE (NCT00075998) and RIFF Cohort A (NCT01872689). An additional analysis included data from pirfenidone-treated patients. Outcomes (annualized change in percent predicted forced vital capacity [%FVC], percent predicted carbon monoxide diffusing capacity, 6-min walk distance, St. George's Respiratory Questionnaire total score, hospitalization, mortality, and serious adverse events) were analyzed by baseline BMI (<25 kg/m2, 25 kg/m2-<30 kg/m2, or ≥30 kg/m2) and annualized percent change in body weight (no loss, >0-<5% loss, or ≥5% loss). Results - Placebo-treated patients with a baseline BMI <25 kg/m2 or annualized weight loss may experience worse outcomes versus those with a baseline BMI ≥25 kg/m2 or no weight loss. The proportion of placebo-treated patients who experienced a relative decline of ≥10% in %FVC or death up to 1 year post-randomization was highest in patients with a baseline BMI <25 kg/m2. Pirfenidone-treated patients with an annualized weight loss ≥5% may also experience worse outcomes versus those with no weight loss. Conclusions - Patients with a baseline BMI <25 kg/m2 or annualized weight loss of >0-<5% or ≥5% may experience worse outcomes over 1 year versus those with a baseline BMI ≥25 kg/m2 or no weight loss.
Fichier principal
Vignette du fichier
Jouneau et al - 2021 - Post hoc Analysis of Clinical Outcomes in Placebo- and Pirfenidone-treated Patients -BMI manuscript_resubmission draft_updated_12JULY21_CLEAN.pdf (1.02 Mo) Télécharger le fichier
Jouneau et al - 2021 - Post hoc Analysis.pdf (268.48 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03349614 , version 1 (20-09-2021)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Stéphane Jouneau, Bruno Crestani, Ronan Thibault, Mathieu Lederlin, Laurent Vernhet, et al.. Post hoc Analysis of Clinical Outcomes in Placebo-and Pirfenidone-treated Patients with IPF Stratified by BMI and Weight Loss. Respiration, 2022, 101 (2), pp.142-154. ⟨10.1159/000518855⟩. ⟨hal-03349614⟩
84 Consultations
54 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More